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Abstract
Schistosomiasis is the second most prevalent parasitic disease in the world. Currently,
the treatment of  this disease relies on a single drug,  praziquantel,  and due to the
identification of resistant parasites, the development of new drugs is urged. The demand
for  the  development  of  robust  high‐throughput  parasite  screening  techniques  is
increasing as drug discovery research in schistosomiasis gains significance. Here, we
review the most common methods used for compound screening in the parasites life
stages and also summarize some of the methods that have been recently developed. In
addition,  we  reviewed  the  methods  most  commonly  implemented  to  search  for
promising targets and how they have been used to validate new targets against the
parasite Schistosoma mansoni. We also review some promising targets in this parasite and
show the main approaches and the major advances that have been achieved by those
studies. Moreover, we share our experiences in schistosomiasis drug discovery attained
with our S. mansoni drug screening platform establishment.
Keywords: Schistosoma mansoni, drug screening, histone‐modifying enzymes, protein
kinases, inhibitors, RNA interference
1. Introduction
Schistosomiasis is a chronic parasitic disease caused by flatworms of the genus Schistosoma.
The main species of medical relevance are Schistosoma mansoni, Schistosoma japonicum, and
Schistosoma haematobium, which infect around 258 million people worldwide, causing 300,000
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deaths yearly, according to WHO statistics. The economic and health effects of schistosomiasis
are considerable as this disease can be highly debilitating. To date, there is no licensed vaccine
against the disease, and treatment is based on a single drug, praziquantel [1, 2]. Despite its
effectiveness, the heavy reliance on a single drug bears a risk of drug resistance development
and, indeed, resistant parasites have already been reported [3–7]. Additionally, praziquantel
presents poor efficacy against immature schistosome life stage,  and there is no pediatric
formulation available. Hence, drug discovery in schistosomiasis is still of great importance.
2. Drug screening techniques in schistosomiasis
Several approaches are used to search new drugs for infectious diseases. Among them, we can
highlight: selective, empirical, biochemical, and genomic approaches. In the selective ap‐
proach, compounds targeting molecules important for parasite survival and/or development
(a “chokepoint”) are tested. The empirical method consists of a blind random test of a large
number of compounds, without any previous knowledge. The biochemical approach verifies
whether the compounds are capable to change parasite metabolism. Finally, the genomic
approach aims to search for new drug targets based on parasite and/or host genome analysis
[8, 9].
Drug screening in Schistosoma has been performed using a myriad of techniques and, most of
the time, using a single life stage. In order to optimize drug screening in a parasite presenting
such distinct and complex life cycle, the search for inhibitors must be performed in the different
human infecting life cycle stages such as the schistosomula and adult worms (males and
females) as drug sensitivity can differ between the stages and sexes [7]. The screening should
also be conducted in vitro and in vivo since drug activity can be diverse in different systems.
A wide range of in vitro methods for drug screening in S. mansoni is described; however,
microscopic observation to identify the presence of intracellular granularity and changes in
the shape and movement of the parasite remains the most used technique, and it is considered
the “gold standard” for parasite viability evaluation [10, 11]. However, this analysis can be
subjective: (1) it relies in one observing person; (2) schistosomula may exhibit characteristics
of dead specimens even when viable [12]; and (3) it is time consuming.
Recently, new methods based on high‐throughput (HTS) and whole‐organism screens in
helminths have emerged. The HTS method is based on screening a parasite target against a
large number of compounds in parallel (minimum of 10,000) and may be performed manually
or automatically using robotic systems [13–15]. In contrast, the whole‐organism screen intends
to test a small number of compounds against the pathogen and the drug effect is usually
individually analyzed [16]. These new methods monitor the parasite by video, impedance,
enzymatic activity, colorimetry, and fluorimetry among others [17–23].
An example of fluorimetric method is the quantification of lactate excreted by the parasite in
the culture medium. The parasite tegument presents two glucose transporters, SGTP1 and
SGTP4, which acquire glucose present in the host bloodstream [24]. Lactate is the final product
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after glycolysis, and it is excreted through aquaporin SmAQP, an aquaglyceroporin homo‐
logue [25]. The amount of lactate excreted by the parasite can be measured by fluorimetric
assays with probes that bind to lactate and emit fluorescence. The measurement of lactate
produced by cells has frequently been used for the analysis of cells or whole‐organism
viability [26, 27]. This method was used by Howe and collaborators [17] and was proved
feasible in S. mansoni, owing to its sensitivity to measure the viability of adult worms and
schistosomula.
Fluorescence viability analysis in schistosomula was also performed by Peak and collabora‐
tors [23] combining the use of propidium iodide (PI) (544 nm excitation/620 nm emission) and
fluorescein diacetate (FDA) (485 nm excitation/520 nm emission). The PI intercalates into DNA
if the membrane of cells is permeable in damaged or dead parasites, but in viable schistoso‐
mula, PI is incapable to cross the membrane. Breach of the membrane permeability allows PI
to stain nucleic acids. On the other hand, FDA is able to penetrate the membrane of live
schistosomula, and due to the parasite esterase activity, it is converted into a highly fluorescent
and charged fluorescein, and FDA cannot readily exit living cells. This test requires a fluores‐
cence inverted microscope to evaluate each spectrum. However, even without a fluorescence
readout, staining with PI is a quantitative, simple and low‐cost method that has been used for
a long time for viability evaluation in S. mansoni by our group [28].
The blue dye resazurin has been widely used in drug testing in Trypanosoma and Leishmania
species [29, 30]. This method relies on an oxidation‐reduction reaction, wherein resazurin
suffers a colorimetric change in response to cellular metabolic reduction. The reduced form is
pink, and thus, the intensity of fluorescence produced is proportional to the number of living
cells. Despite being described as an effective drug test for S. mansoni and demonstrating that
they were able to detect schistosomula viability, its use is questionable since, when compared
to the visual test, this method showed low sensitivity [22]. In our hands, this method has proven
very variable among replicates and requires a very specific fluorescence plate reader.
Movement‐based assays are widely used for anthelmintic drug screening in adult worms and
might be the first phenotype tested in most screenings, whereas movement measures are not
explored as much for testing viability of the S. mansoni larval stage. Kotze et al. [31] performed
visual assays to test drug sensitivity in Strongyloides species. This method consisted in scoring
the larvae that exhibited movement after 48 h of drug incubation and stimulation with hot
water. The approach proved to be an efficient assay for testing new drugs and for detection of
resistance; nevertheless, it is quite subjective. Meanwhile, Paveley et al. [19] performed a
phenotype analysis in S. mansoni schistosomula exposed to drugs. The authors developed an
image‐based method that collects images in time‐lapse every 6 s and analyzes the cumulative
change in the area occupied by each schistosomulum. The researchers concluded that this
method is suitable for drug screening in schistosomula, although requiring a complex analysis
involving machine training.
Recently, Rinaldi et al. [11] have adapted a cell viability method, which is based on impedance,
called xCELLigence, to evaluate the movement of cercariae, schistosomula and adult worms,
and measure egg hatching of S. mansoni. This assay consists in analyzing the changes in electric
conductivity due to parasite contact with electrodes; therefore, more parasite movement is
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measured as a large electric conductivity change. The possibility of using this method in drug
screening using cercariae, adult worms, and eggs was also verified. However, this method is
at a preliminary stage of standardization, since only one drug was tested and exhibited large
variation across electrical frequencies tested; in addition, the cost of the equipment and its
plates is elevated.
A very promising method that provides a viability assay in a high‐throughput fashion and
with semiquantitative measurements of movement of helminth worms was developed by
Marcellino and collaborators [18]. This method has demonstrated to be efficient and sensitive
for drug screening using S. mansoni adult worms, since worm movement is considered an
important parameter for high performance tests. In this assay, a video camera and a free
software, called WormAssay, are required and output adult worm movement units. The
smaller the value of movement units generated by the software, the lower the parasite viability.
Later, this methodology, named it as Worminator, was adapted to be used with microscopic
parasites as third‐stage larvae of Cooperia spp. and Brugia malayi and Dirofilaria immitis
microfilariaes. Therefore, Worminator could be an efficient alternative for measuring schisto‐
somula motility [32].
Another promising method based on video capture was developed by Lee and collaborators
[14]. This assay is an automated method to analyze images of schistosomula or other parasites
in 96, 384, or 1536 well plate format and qualify innumerous phenotypes. A machine‐trained
algorithm was able to quantitatively describe the following characteristics: size, shape,
movement, texture, and color. With this method, it is possible to perform a high‐throughput
whole‐organism drug screening. The web server called quantal dose‐response calculator
(QDREC), which was described by Asarnow and collaborators [33], is based on this method‐
ology. QDREC compares drug‐treated parasites with untreated parasites and automatically
determines dose‐response. This method is the only automated method to date that provides
EC50 (half maximal effective concentration) values based on phenotypic analysis. QDREC was
validated using schistosomula and proved to be a high‐throughput and reliable method.
For in vivo assays, mice are suggested as the animals of choice, owing to their susceptibility to
experimental infection [8, 34]. Thus, mice are infected with cercariae and treated with drugs.
After infection, one should observe eggs and granuloma numbers in the liver and intestine,
oogram alterations, and number of adult worms recovered after perfusion [35]. This method
has been employed using single or combination of praziquantel and in association with
lovastatin, clonazepam, among others.
3. Case studies
In order to perform in vivo assays, mice infected with S. mansoni for 45 days were treated with
a single dose of imatinib. After 15 days of treatment, the animals were killed and perfused. In
vitro tests with imatinib impaired movement of adult worms; however, when mice were treated
with this drug, no alterations were found in the oogram and adult worm recovery, demon‐
strating the need of a complete assay during drug screening [36]. In addition, Pereira and
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collaborators [37] tested the compound (−)‐6,6'‐dinitrohinokinin (DNK), a dibenzylbutyrolac‐
tone lignin, using in vitro and in vivo assays. This compound seems to affect the development
and reproduction of the parasite as it caused reduction in adult worm recovery and signifi‐
cantly decreased egg count, corroborating the results of in vitro tests. These findings reaffirm
the need for in vivo testing to confirm drug efficacy, since the biological effects highly rely on
host metabolism.
Drug combinations for infectious diseases therapy represent an alternative to retard drug
resistance. Based on that premise, Araújo et al. [38] treated infected mice with a single dose of
clonazepam associated with praziquantel or oxamniquine. The results showed alterations in
the oogram and a higher number of dead worms recovered from liver of mice treated with
both clonazepam and praziquantel, in comparison with mice treated only with praziquantel.
In another study, the association of praziquantel and oxamniquine with lovastatin was
investigated in vivo, and a higher number of dead adult worms, as well as oogram changes,
were observed in mice treated with the combination lovastatin and oxamniquine compared to
animals treated with praziquantel [38]. These findings suggest that drug combination is a
promising alternative for schistosomiasis treatment.
Thus, it is highly relevant to follow systematic procedures during drug screening. Here, we
present a schematic workflow of the above‐mentioned methods and different life stages that
could be included in drug screening experiments (Figure 1).
Figure 1. Schistosoma mansoni compound screening methods. The workflow represents in vivo and in vitro assays which
can be employed for drug/compounds screening in S. mansoni.
4. Establishment of an anti‐Schistosoma mansoni drug screening platform
The absence of efficient alternative for schistosomiasis treatment demonstrates the need for
new research involving the development of new schistosomicidal compounds. Accordingly,
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development of a S. mansoni drug screening platform, which aims at the study of compound/
drug efficacy in different parasite life stages using distinct methodological approaches is
required. To date, our group has immersed in this field seeking new methodologies, stand‐
ardization of existing ones, and validation of results between different laboratories working
in the field. It is important to highlight that Schistosoma strains vary in response to treatment,
and in order to attain relevant leads, a concerted effort is important. Here we present some
data of drug screening in schistosomula and adult worm stages and the comparison of four
in vitro methodologies.
For drug screening in schistosomula, the methods of choice were: resazurin fluorescence assay,
lactate quantitative analysis, and visual assay using propidium iodide staining (PI). In order
to perform drug screening in adult worms, the movement analysis software WormAssay was
employed.
The standardization for schistosomula drug screening was performed using 96‐well plate
format with 100, 200, 400, 600, and 800 parasites per well. Schistosomula were submitted to
three different treatments: parasites exposed to 0.1% dimethyl sulfoxide (DMSO; vehicle
control); heat‐killed parasites (negative control); and parasites exposed to 20 μM of the sirtuin
inhibitor Salermide (half maximal inhibitory concentration—IC50). Lancelot et al. [39]
demonstrated that Salermide induces death and apoptosis of schistosomula, separation of
adult worm pairs, as well as a reduction in egg laying.
The PI staining procedure was established by the use of 5 μg/mL of fluorophore into 96‐well
culture plates containing 100 parasites and visualized in inverted fluorescence microscope.
Our results have shown that mortality evaluation by phenotype observation in bright‐field
light microscope was overestimated when compared to PI staining results. This result rein‐
forces the subjectivity problem of bright‐field visual analysis since parasites that presented a
dead phenotype (intracellular granularity and absence of movement) not always stain with PI,
indicating their viability.
In viability assays using resazurin, we observed large variability between technical and
biological replicates and a low value of relative fluorescence units (RFU). Mansour and Bickle
[22] described RFU values >1000 in wells containing 100 schistosomula, and such high RFU
values were possible only with 500 parasites per well in our assays conditions. Overall, using
this fluorescence assay, we were unable to discriminate schistosomula killed by Salermide
treatment from the vehicle control (0.1% DMSO). Issues in assay sensitivity measured by RFU
values could be due to differences in the fluorescence reader platform, indicating that the assay
can present a reproducibility issue. Limitations in this methodology such as low sensitivity
and reliability, when compared to visual analysis, were described by the authors who proposed
the application of resazurin as S. mansoni viability test [22].
Standardization of lactate quantitative analysis demonstrated low variability and significant
differences between RFU values of schistosomula exposed to 20 μM Salermide from 0.1%
DMSO. RFU values were similar to those described in the work of Howe and collaborators [17]
confirming the method's reproducibility. Mortality of the parasites detected in the lactate
quantitative analysis was confirmed by PI staining and observation under the microscope, in
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contrast to our previous results with resazurin assay. Considering the fluorescence‐based
viability assays, lactate quantitative analysis has shown to be more reliable in our hands.
However, the test may also be subject to interference, since some compounds crystallize in
contact with culture medium and can emit fluorescence at the wavelength utilized (530 nm
excitation/590 nm emission).
The use of viability assays that target schistosome metabolism is important for drug screening,
since some drugs may reduce parasite viability but do not cause parasite death, and hence
these parasites may not stain by PI. Therefore, we believe that the combination of these two
approaches to evaluate parasite viability/mortality is a good strategy for drug screening as
they are complementary methodologies.
Regarding adult worm drug screening, Howe and collaborators [17] proposed the use of one
male adult worm per well exposed for 72‐h treatment with praziquantel and mefloquine, and
detected a reduction in medium lactate. The use of only males and one parasite per well does
not validate this methodology for drug testing in adult worms, as males and females may react
differently to treatments and each individual has distinct susceptibility/metabolism. Therefore,
the use of this method would require larger number of worms including both sexes.
The method of trematode movement analysis using impedance was described by Smout and
collaborators [20] and was recently validated in S. mansoni [11]. In this study, one worm per
well was also challenged and wide variation in sensitivity of the experiment was reported due
to variation in the electric frequency (kHz). Due to the limitations in those methods, we
implemented the WormAssay [18] to analyze adult worm exposure to drugs.
In our platform, eight adult worms were established as the minimum number of specimens to
be analyzed. Most importantly, paired females and males should not be analyzed because a
drug could be active in only sex, disturbing the movement analysis due to female presence in
male gynaecophoric channel. The plates containing the worms are filmed for 1 min and 30 s
every day for 10 days. The software is freely available for download, recognizes the wells, and
provides the total of movement units for each. Moreover, handling is simple and our tests
confirm its sensitivity and accuracy.
For validation of our anti‐S. mansoni drug screening platform, we used epigenetic modification
factor inhibitors. A total of 137 compounds were tested on S. mansoni schistosomula and adult
worms as part of the A‐PARADDISE consortium (http://a‐paraddise.cebio.org/) using the
visual assay with PI, the quantitative analysis of lactate for schistosomula, and the WormAssay
for adult worms. Among these compounds, 114 (83%) exhibited some effect on the parasite.
From 114 active compounds, 29 were active in all methods used, and in both sexes and stages
tested, 12 compounds were active only in schistosomula, 35 were active at least in one sex of
adult worm and, among them, 24 were active only in female worms (Figure 2).
These data confirm the need to perform an assay aimed at identifying compounds capable of
altering the parasite metabolism and, consequently, their viability, since the compound cannot
cause parasite death, hindering the observation of drug effect in a visual assay. Clustering
methodologies, life stages, and parasite strains could change the outcomes of large screening
studies such as those using a single method and stage; for example, Li et al. [40] performed a
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screening of 59,360 thioredoxin glutathione reductase (TGR) inhibitors against S. mansoni
thioredoxin glutathione reductase (SmTGR) recombinant protein using a fluorometric assay,
74 were active and tested in S. mansoni, and among them, 53% were active in schistosomula
and only 2.7% were effective against adult worms. Additionally, Yousif et al. [41] carried out
a screen of 309 plant extracts on adult worms employing visual analysis of viability and
identified 14% as active.
Figure 2. Venn diagram of the active compounds tested in propidium iodide, lactate quantification, and WormAssay.
The diagram represents the distribution of the active compounds according to stage and used methods. The schistoso‐
mula assay using staining with PI is identified by the color green, schistosomula assay using the quantitative analysis
of lactate is identified by the color yellow, the test in male adult worms by WormAssay is indicated by the color blue,
and the test in female adult worms by WormAssay is represented by the color red.
Our work demonstrates the need to use parallel and complementary methods, since only using
PI, for example, a lower number of compounds would be selected as active and consequently,
potential compounds would be excluded. In view of the foregoing methods, the contributions
from studies aimed at identifying new therapeutic compounds against schistosomiasis could,
perhaps, be most effective if they employ more than a single method for screening drugs and
different parasite stages. The association of fluorescence with PI staining enables the selection
of compounds capable of altering parasite viability and/or inducing mortality. Moreover, male
and female adult worms develop and have different metabolisms, and thus, their susceptibility
to a specific drug also differs. One clear example is the studies demonstrating that female adult
worms are more sensitive to praziquantel than males [4, 42] and approximately 1341 genes are
up‐regulated in female adult worms when compared to male [43]. Regarding the different life
stages, results demonstrate that some drugs, including praziquantel, are active solely in the
mature stage of S. mansoni [44].
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These results indicate the need to employ different methods for drug screening as one can find
a larger number of hits than when the tests are performed using only one method or in only
one stage of the parasite. In addition, it substantiates the importance of using the selective
approach to find active compounds, thus using a rational approach targeting previous
validated targets, allowing direct design of specific compounds.
5. Validation of S. mansoni drug targets
The most common strategies used in drug discovery are the empirical and the rational
approaches. The first is based on testing various compounds randomly looking for biological
activities. The second is also called the selective approach as it proposes identifying a biological
target and then designing or looking for a specific inhibitor for that target. In this sense, there
are many strategies to assess gene function in parasites in order to elucidate their role in
development, mechanisms of drug resistance, and speculate its use as a parasite control
method. Among them, we can mention comparative “omics,” RNA interference, heterologous
complementation using model organisms (i.e., Caenorhabditis elegans) and in silico approaches.
Comparative “omics” has been used to identify potential target proteins that appear to be
essential for the parasite, while RNA interference has been used to validate a variety of drug
target molecules, such as histone‐modifying enzymes (HMEs), protein kinases, and others.
5.1. Histone‐modifying enzymes
Among the most studied targets are epigenetic modulators, and among them are regulators
of chromatin epigenetic modifications, named histone‐modifying enzymes (HMEs), which act
on the epigenome resulting in a change in the gene transcription profile. HMEs are involved
in a wide range of reactions including methylation, demethylation, acetylation, deacetylation,
phosphorylation, ADP‐ribosylation, deimination, sumoylation, ubiquitination, etc. Yet, recent
findings have described a myriad of lysine modifications, among others: formylation, succi‐
nylation, crotonylation, and malonylation [45].
The enzymes involved in the insertion and removal of methyl groups are called histone
methyltransferase (HMT) and histone demethylases (HDM) [46]. The histone‐modifying
enzymes involved in the insertion and removal of acetyl groups are called histone acetyltrans‐
ferases (HAT) and histone deacetylases (HDAC and sirtuins). Acetylation of lysine residues
and methylation of lysine and/or arginine residues in histones H3 and H4 tails are two changes
of particular importance [47, 48]. The insertion of acetyl and methyl groups neutralizes the
positive charge of histones, destabilizing the structure of nucleosome and allowing the DNA
to separate from histones. This results in the facilitation of the access of transcription factors
and RNA polymerase to the DNA stimulating gene expression. The removal of these groups
has the opposite effect, increasing the positive charge, condensing chromatin, and thereby,
repressing transcription [49]. The heterochromatin is transcriptionally inactive when highly
methylated at lysine 9 of histone H3 and not methylated at lysine 4, and hypoacetylated in
histones H3 and H4 [50]. It is important to highlight that HDACs and sirtuins also deacetylate
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other nonhistone substrates such as chaperones, peroxiredoxins, transcription factors,
signaling mediators, and structural proteins (e.g., [51–55]).
These modifications allow specific combinations that affect the overall structure of chromatin
and the transcription of genes, the so‐called histone code, which is, in many cases, conserved
among organisms [50]. Aberrant epigenetic states are often associated with human diseases
such as cancer, inflammation, metabolic, and neuropsychiatric disorders, and thus HMEs are
implicated and intensively studied as therapeutic targets in various diseases [56–59].
One of the most promising approaches for drug discovery among HMEs is the development
of HDAC inhibitors, which targets the highly studied lysine deacetylases. These targets are
also key for parasites, including schistosomes, which present, similarly to tumors, dependence
on lactate fermentation as energy source, host independent growth, high metabolic activity,
and host immune evasion through mimetism of molecules [60]. In addition to schistosomes,
HMEs have been highly explored as drug targets for parasitic diseases such as Trypanosoma
brucei, Plasmodium falciparum, Leishmania spp., Toxoplasma sp., among others [61–63].
Many different types of HDAC inhibitors (HDACi) are under development. The inhibitors
targeting class I and II HDACs are classified into four families according to their structure:
inhibitors containing short‐chain fatty acids (butyrate and the valproic acid—VPA), com‐
pounds derived from hydroxamic acid (the Trichostatin A—TSA and the acid‐suberoylanilide
hydroxamic—SAHA or vorinostat), and the group of cyclic tetrapeptides and benzamides.
Among these inhibitors, SAHA was approved by Food and Drug Administration (FDA) for
use in adult individuals with cutaneous T‐cell lymphoma [64]. In vitro tests with butyrate, VPA
and TSA, performed with human cells demonstrated that these inhibitors lead to apoptosis,
differentiation, and cell cycle arrest [65].
Some studies have shown that HDACi, such as TSA, triggers histone H4 hyperacetylation in
S. mansoni schistosomula at low concentration (2 μM), leading to apoptosis and affecting
significantly gene transcription [66, 67]. According to Pierce and collaborators [65], in vitro
exposure of schistosomula and adult worms with VPA inhibitors (TSA and SAHA) inhibited
80% of the total HDAC activity and caused the death of parasites.
In addition to pan HDAC inhibitors, one international consortium has been focusing in
strategic epigenetic druggable targets for diverse parasites [65]. Recently, SmHDAC8 has risen
as a promising target to treat schistosomiasis. First, SmHDAC8 was validated and proved to
be essential for parasite infectivity, since parasites knocked down for SmHDAC8 were unable
to normally develop in the mammalian host and showed, approximately, 50% reduction in
oviposition [68]. Structural analysis has also shown that HDAC8 of S. mansoni presents
important structural differences when compared to the human orthologue, despite a single
amino acid substitution in the active site [68]. In this work, schistosomula larvae were exposed
to hydroxamate derivative, HDAC8‐specific inhibitor (J1075), which led to apoptosis and
parasite death. These studies are a proof of concept that HMEs are important therapeutic
targets, and potential new drugs based on HDACi can be developed against schistosomiasis.
To date, a way to expand the repertoire of specific Schistosoma, HDACi is utilizing a “piggy‐
back” strategy, which accelerates the exploration for novel antischistosomal compounds. These
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strategies are founded in the principle of using structure‐based inhibitors, previously validated
for other illnesses or other targets, to add a variety of chemical scaffolds and backbones,
facilitating the development of selective inhibitors specifically aiming the schistosoma HMEs
[69].
Besides deacetylases, HAT inhibitors and some derivatives of medicinal herbs, such as
curcumin, also demonstrated their potential as inhibitors, since they induce hypoacetylation
and lead tumor cells into apoptosis [70, 71]. Magalhães and collaborators [72] demonstrated
the efficacy of curcumin in S. mansoni. In this study, the authors reported that in the presence
of curcumin (5 and 20 μM), adult worms lose 50% of viability and reduce oviposition, and
higher concentrations (50 and 100 μM) cause 100% mortality of worms. These data corroborate
the results observed by our group, that 20 μM of this KDM1 and HAT inhibitor, causes a 95.5%
motility reduction of female adult worms, confirming the importance of LSD1 and HAT for
the development of S. mansoni (unpublished data).
Recent studies in S. mansoni demonstrated that the HAT inhibitor, PU139, at a high concen‐
tration (50 μM), affects adult worm pairing, the reproductive system of female adult worms,
and the maturation of viable eggs [73]. In our hands, with a lower dose (20 μM), this compound
was able to reduce female motility, confirming that it is active in the worm and highlighting
the aforementioned (Section 2) necessity of assaying drug tests in female and male separately
in order to reduce false negatives in drug screening in schistosomes.
Studies using HMT and HDM inhibitors are less common, but some results have shown that
the chloroacetyl derivative, allantodapsone, a PRMT1 (arginine methyltransferase) inhibitor,
showed selective inhibition affecting the growth of tumor cells [74]. Inhibitors of KDM1 (LSD1),
a histone demethylase, are considered promising compounds for cancer therapy [75]. Studies
performed by our group, knocked down for PRMT3 and KDMs in schistosomula by RNA
interference, show that these enzymes are important for S. mansoni reproduction (unpublish‐
ed data).
Due to the wide range of HME functions as “erasers” and “writers” of the epigenome, boosted
by the use of histone and many nonhistone protein substrates, and taking into account the
cellular localizations of these enzymes, it has been demonstrated, as expected, that they are
essential and attractive targets for development of therapy for a number of infectious diseases,
including schistosomiasis.
5.2. Protein kinases
The Schistosoma complex life cycle involves different life stages and requires sophisticated
coordination of its physiological systems to ensure success of infection and survival in both
hosts. Therefore, signals of the environment and hosts stimulate physiological, morphological,
and biochemical changes [76, 77]. It involves nonlinear signaling networks that switch protein
activity by phosphorylation (by protein kinases—PKs) and dephosphorylation (by protein
phosphatases) of amino acid residues, or by incorporation of GTP. Protein kinase phosphory‐
lation and the subsequent activation of signaling cascades result in the activation of transcrip‐
tion factors that target specific genes promoting or blocking their transcription. Furthermore,
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they can alter enzymatic activity, interaction with other proteins and molecules, cellular
localization, and susceptibility to proteases degradation [78].
Eukaryotic protein kinases (ePKs) participate in phosphorylation cascades that regulate
diverse cellular processes. PKs are among the largest gene families in eukaryotes and have
been extensively studied and considered potential targets for drug development. The devel‐
opment of PK inhibitors has culminated in the approval of some drugs for the treatment of
various human diseases such as cancer and diabetes. Furthermore, PKs have gained interest
as potential drug targets against many parasites, including S. mansoni [79–82].
The S. mansoni predicted proteome is composed of about 2% of PKs, a total of 252 proteins, of
which only about 30 have some functional experimental evidence [83]. The scarcity of data on
S. mansoni PKs has motivated studies that will contribute to a better understanding of the roles
of this protein family in parasite development and survival.
Four mitogen‐activated protein kinases (MAPKs) were studied by our group using double‐
stranded RNA‐mediated interference to elucidate their functional roles. Mice were infected
with schistosomula after gene knockdown, and the development of adult worms was ob‐
served. Andrade et al. [79] showed that c‐Jun N‐terminal kinase SmJNK participates in the
maturation and survival of the parasite, associated with the presence of undifferentiated
oocytes and damage in the adult male tegument. SmERK‐1 and SmERK‐2 are involved in egg
production, since females were recovered with undeveloped ovaries and immature oocytes,
and the infected mice harbored significantly fewer eggs. Furthermore, the Smp38 kinase seems
to have an important role in the development and survival of parasites and in their protection
against reactive oxygen species (unpublished data). Thus, we demonstrated that MAPK
proteins are important for parasite survival in vivo and are essential for the development and
reproduction of the parasite.
Guidi et al. [84] used RNA interference to investigate the function of 24 proteins in adult worms
and schistosomula, and among those, kinases were included. For atypical protein kinase C
(SmaPKC), knockdown resulted in decreased viability in both stages. Knockdown of polo‐like
kinase 1 (SmPLK1) and p38 MAPK (Smp38) increased mortality only in larvae. The SmPLK1
inhibition with BI2536, a specific inhibitor, also increased mortality and interfered with egg
production. Knockdown of SmPLK1 and SmaPKC also resulted in lower worm recoveries in
vivo.
Ressurreição et al. [85] reported that phosphorylation of PKC, ERK, and p38 MAPK kinases is
modulated by light and temperature. Furthermore, in response to linoleic acid, these kinases
appear to coordinate the release of components of the cercarial acetabular gland, and PKC and
ERK, when activated, are located in putative sensory receptors in the tail, thus demonstrating
the importance of PKC, ERK, and p38 MAPK signaling pathways in the mechanisms for host
penetration.
As mentioned, PKs are conserved and widely studied in many organisms; therefore, a range
of PK inhibitors is already available, which are valuable tools. The function of some kinases
was studied by parasite exposure to these inhibitors to explore PK functions in S. mansoni.
Matsuyama et al. [86] demonstrated that cAMP‐dependent protein kinase is involved in the
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osmosis‐regulated ciliary movement of miracidia by exposure to the inhibitors PKI(14‐
22)amide, H89, and H88, verifying the complete inhibition of miracidia swimming in artificial
pond water. Inhibition of protein kinase C (SmPKC) by GF109203X accelerates the rate of larval
development of S. mansoni, with miracidia shedding its ciliary plates significantly faster and
developing into mother sporocyst [87]. Another example, the polo‐like kinase SmPlk1 has a
potent and selective inhibitor (the anticancer drug BI 2536), which induces changes in schis‐
tosome gonads, an indication that SmPlk1 participates in parasite gametogenesis [88]. More
recently, Long et al. [89] showed that knockdown of SmPlk1 using RNA interference induced
abnormal phenotypes in schistosomula. They also tested a panel of 38 benzimidazole thio‐
phene PLK1 inhibitors and 11 commercially available human PLK1 inhibitors in schistosomula
and adult worms using microscopical observation and the QDREC approaches to verify
changes in the parasite. Many of these inhibitors caused deleterious changes in the parasite.
Knobloch et al. [90] used the inhibitor Herbimycin A to demonstrate that protein tyrosine
kinases (PTKs) regulates gonad development and egg production through changes in gene
expression of eggshell proteins, and suggested PTKs as novel anti‐Schistosoma drug targets.
Transcriptome analyses of female worms after treatment with the inhibitors Herbimycin A and
TRIKI, or both, revealed a number of genes that were transcriptionally affected. Herbimycin
A specifically inhibited the Src kinase SmTK3, and TRIKI (TGF‐β receptor type I kinase
inhibitor) inhibited the TGFβ receptor, SmTβR. The expression of genes with recognized
function in eggshell formation was investigated using quantitative polymerase chain reaction
(qPCR) and proved to be regulated by the signaling pathways containing Src and TβRI [91].
Imatinib, an Abl‐kinase‐specific inhibitor used in human cancer therapy, was tested against
adult worms and caused effects on morphology and physiology of S. mansoni couples in vitro
[92]. Transcriptome analyses of adult worms treated with imatinib were performed using
microarray and qPCR. Genes related to surface, muscle, gut, and gonad processes were
differentially expressed. In addition, a comparative analysis of microarray data with previous
data after TRIKI inhibition was performed and provided evidence of an association between
TGFβ and Abl kinase signaling pathways [93].
Syk kinase (SmTK4) function was studied in adult worms using RNA interference and the
specific inhibitor piceatannol. Prominent morphological changes in testes and ovaries were
observed, demonstrating the role of SmTK4 in gametogenesis. In addition, the authors used
yeast two‐/three‐hybrid library screenings and identified a Src kinase (SmTK6) acting up‐
stream and a MAPK‐activating protein and a mapmodulin acting downstream of SmTK4 [94].
A set of commercial kinase inhibitors was tested by Morel et al. [95] in schistosomula and adult
worms, conforming deleterious effects on parasite physiology, as well as the importance of
kinases in parasite biology and reproduction. In that study, five protein kinase B (SmPKB or
SmAkt) inhibitors were tested and three affected pairing and oviposition of adult worms, in
addition cause mortality in larvae. These data, along with other studies [96], suggest that
SmAkt is a key regulator of schistosoma reproduction processes [95].
The roles of protein kinases C (PKCs) and extracellular signal‐regulated kinases (ERKs) were
studied through modulation of PKC and ERK activity by kinase activators and inhibitors in
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adult worms. Results have shown that this modulation induced worm uncoupling, suppressed
egg output, male worm detachment, worm paralysis, and provoked sustained coiling. The
authors also reported that praziquantel, the drug of choice for schistosomiasis treatment,
induced activation of S. mansoni PKCs and ERKs. Activated PKC and ERK in adult worms are
associated with muscular, tegumental, and reproductive structures [97].
5.3. Other targets
In addition to epigenetic modification, effectors and protein kinases, numerous proteins
related to proteolytic, xenobiotic metabolism, redox processes, nucleotide biosynthesis and
proteins involved in the nervous system of Schistosoma have been tested as therapeutic targets.
5.3.1. Peptidases
Peptidases are enzymes that perform proteolytic reactions and peptide bond hydrolysis.
Schistosoma mansoni peptidases are attractive drug targets because they act in the host‐parasite
interaction during parasite invasion, migration, nutrition, and immune evasion [98]. The
parasite serine peptidase involved in skin penetration of the human host, called cercarial
elastase (SmCE), has been well studied [99, 100]. SmCE could have a role in immune evasion,
as a highly purified SmCE was able to cleave IgE and other key molecules involved in immune
regulation [101]. The use of serine protease inhibitors prevented IgE cleavage by cercariae and
schistosomula extracts in a previous study, indicating that this could be a promising path for
therapeutic strategies [102].
The S. mansoni cysteine and aspartic peptidases have drawn attention of many researchers as
they participate in digestion of the blood meal. A previous study has shown that the use of
inhibitors of these peptidases impairs hemoglobin degradation and arrests schistosome
development and egg production [103]. The S. mansoni cathepsin B1 (SmCB1), which is a highly
abundant digestive protease, was the focal point of various studies (reviewed in Ref. [104]).
SmCB1 has been validated as a molecular target for therapy against schistosomiasis in a murine
model of S. mansoni infection [105]. Moreover, SmCB1 crystal structure was determined, and
specific inhibitors were designed, which are potential drug leads [106–108]. Another schisto‐
some aspartic peptidase under study as a target is cathepsin D (SmCD). Morales et al. [109]
have shown that silencing SmCD transcripts by RNA interference promoted schistosomula
growth retardation as well as reduced worm and egg burden in infected mice. SmCD is
currently under consideration for vaccine development against S. mansoni [110].
Prolyl oligopeptidases of the S9 family of serine peptidases have been investigated in S. mansoni
by Fajtová et al. [111] who characterized the S. mansoni prolyl oligopeptidase (SmPOP) activity
and showed that it is localized in the tegument and parenchyma of adult worms and schisto‐
somula. Additionally, the authors designed specific inhibitors of SmPOP that were able to
induce schistosoma death, suggesting that SmPOP could be a potential target for antischisto‐
somal drug development.
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5.3.2. Xenobiotic metabolism
The biotransformation of xenobiotics involves pathways that can be divided into three phases:
(I) oxidation, reduction, or hydrolysis of xenobiotics; (II) conjugation of metabolites with
endogenous compounds; and (III) excretion of modified molecules through membrane‐bound
transport proteins [112]. The xenobiotic metabolism can be a promising area for drug devel‐
opment since it implicates mechanisms that the parasite uses to eliminate drugs or toxic
compounds; additionally, it plays vital roles in providing essential molecules for parasite
survival. Among the S. mansoni biotransformation proteins, the phase I enzyme CYP450 has
been studied by Ziniel et al. [113] who demonstrated that CYP450 RNA interference‐mediated
knockdown resulted in worm death. Additionally, imidazole antifungal CYP450 inhibitors had
schistosomicidal activity against adult and larval worms, and blocked embryonic development
in the egg.
The glutathione S‐transferase (GST) family, from biotransformation pathway phase II, has been
extensively studied in schistosomes. The knockdown of SmGST26 and SmGST28 in sporocysts
by dsRNA exposure increased their susceptibility to exogenous oxidative stress and to
Biomphalaria glabrata hemocytes‐mediated killing [114]. The GST family of proteins is currently
important vaccine candidate as it has been shown that these enzymes bind to several com‐
mercially available anthelmintics [115, 116].
The phase III membrane‐bound transport proteins are currently under study, and the ABC
transporters are the most studied among them [117]. The involvement of these ABC trans‐
porters such as P‐glycoprotein and multidrug resistance‐associated protein (SmDR1, SmDR2,
SmMRP1, ABCA4, ABCB6, and ABCC10/MRP7) in drug susceptibility and development of
drug resistance in schistosomes is clear, and this makes them excellent candidate targets for
inhibitors that could potentiate the effect of existing drugs against schistosomes [118] or as
new therapeutic targets themselves [119].
5.3.3. Redox mechanisms
Redox balance mechanisms are essential for schistosome worm survival, and differences
between schistosome and human host redox networks were shown in previous studies
(reviewed in Ref. [120]). The S. mansoni thioredoxin glutathione reductase (SmTGR) has been
shown to be an important drug target. The use of oxadiazole‐2‐oxides as novel TGR inhibitors
produced significant activity against various S. mansoni stages ex vivo and in vivo [40, 121,
122]. Another drug target in schistosome redox biology is the peroxiredoxins (SmPrx), which
may be responsible to neutralize H2O2 due to the fact that schistosomes lack the catalase
enzyme, resulting in a limited capacity to cope with this oxidant [120]. Sayed et al. [123] have
shown that SmPrx1 knockdown by dsRNA exposure can potentially lead to schistosome death.
Schistosoma mansoni antioxidant system relevance was also demonstrated in sporocysts by
Mourão et al. [114]. RNAi‐mediated knockdown of glutathione peroxidase (SmGPx), SmPrx1,
and SmPrx2 increased larvae susceptibility to H2O2 oxidative stress. Additionally, treatment
of parasites with SmPrx1/2 dsRNA increased hemocyte‐mediated killing in vitro.
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5.3.4. Purine biosynthesis
The purine nucleotide de novo synthesis pathway is absent in S. mansoni, which makes the
parasite purine salvage pathway an attractive target for antischistosomal therapy develop‐
ment. A key component of this pathway is the purine nucleoside phosphorylase. The S. mansoni
purine nucleoside phosphorylase (SmPNP) activity and structure have been well character‐
ized [124–126]. Selective inhibitors for SmPNP have been tested in enzymatic assays in vitro;
however, experiments with parasite larval or adult stages have not been reported yet [127–
129]. The hypoxanthine‐guanine phosphoribosyltransferase (HGPRTase) was also considered
as a potential drug target [130]. Pereira et al. [131] performed with siRNA directed against
SmHGPRTase the first successful demonstration of an in vivo RNAi‐based treatment against
schistosomiasis.
5.3.5. Neurotransmitter transporters
Schistosoma mansoni nervous system is very well developed with a rich diversity of neuro‐
transmitters. The neurotransmitter serotonin is one of the most abundant neuroactive sub‐
stances in the S. mansoni nervous system [132], stimulating worm movement, muscle
contraction, glycogenolysis, and glucose utilization in schistosomes [133, 134]. The S. mansoni
serotonin transporter (SmSERT) function and localization have been studied [135, 136], and
apparently, it acts as a neuronal transporter playing a key role in serotonergic control of parasite
motility. Some classical selective serotonin reuptake inhibitors that usually target this type of
transporters have shown potent schistosomicidal effect in drug screening [10, 137]. Some of
these inhibitors presented different potency and selectivity for SmSERT when compared to the
human hSERT, indicating that this evolutionary distance could be explored for the develop‐
ment of novel anti‐Schistosoma therapies.
The inhibitory neurotransmitters, norepinephrine (NE) and dopamine (DA), are also present
in S. mansoni, and they cause muscular relaxation and worm body lengthening [134]. A
dopamine/norepinephrine transporter (DAT) from S. mansoni (SmDAT) has been character‐
ized [138], and it would be responsible for clearance of NE and DA following their release to
terminate the signal. SmDAT pharmacological studies showed that its response to tricyclic
antidepressants and to selective serotonin reuptake inhibitors was higher than that shown for
human DAT. Once again, the differences in ligand binding activity of schistosome neurotrans‐
mitter transporters reinforce them as good candidates for selective drug targeting. Neverthe‐
less, inhibitors of schistosome neurotransmitter transporters have not been tested in an animal
infection model yet, so the concerns over psychoactivity and undesirable side effects in the
host could not be ruled out.
5.3.6. Neurotransmitter receptors
The S. mansoni genome sequence predicts several putative neurotransmitter receptors from
the two main classes: ligand‐gated ion channels and G protein‐coupled receptors (GPCR)
[139]. Receptors of neurotransmitters dopamine, histamine, glutamate, serotonin, and
acetylcholine have been cloned and characterized [140–147]. Many of these receptors have
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shown divergences from host receptors in structural and pharmacological aspects, indicating
a possible track for antischistosomal therapy development. MacDonald et al. [148] demon‐
strated through RNA interference phenotypic assay that the knockdown of S. mansoni GPCR
for acetylcholine (SmGAR) can disrupt larval motility. The importance of a serotonin receptor
(Sm5HTR) for parasite motor activity has been also demonstrated by RNA interference [145].
Furthermore, it has been shown that the use of a heterologous system based on a fluorescent
mammalian cell high‐throughput functional assay can contribute as a new tool in the search
for schistosomicidal drugs in the neurotransmitter receptors field [144].
6. Future directions and new approaches
While schistosomiasis still has a high socioeconomic impact, with the total number of disabil‐
ity‐adjusted life years (DALY) lost to schistosomiasis estimated at 4.5 million per year, and
treatment relies only on praziquantel since the early 1980s, drug discovery is still of great
relevance. Our results with a S. mansoni drug screening platform reinforce that the use of
parallel and complementary methods to assess parasites viability is essential in future studies.
Drug discovery studies that employ different methods for drug screening are more prone to
find new lead compounds. Additionally, drug screening should be performed in more than
one parasite stages as some compound may present activity in schistosomula larval stage but
be inactive in the adult worm stage or vice versa. It is worth to mention that praziquantel has
little effect on immature worms; however, this drug acts in <1 h on adult worms damaging the
tegument and paralyzing the worms. A compound that acts in all parasite stages and in both
sexes is desirable, as such drug could be used to combat the acute and chronic phases of
schistosomiasis, as well as to prevent the dissemination of viable eggs.
It is noteworthy that after identifying potential anti‐Schistosoma mansoni drugs, several strict
tests for validation are needed, those include bioavailability, stability, absorption, metabolism,
distribution, excretion/pharmacokinetics, and toxicity in in vivo assays. The present chapter
depicted the most studied drug targets on S. mansoni. The extensive publications on Schistosoma
gene characterization studies and selective inhibitors design may pave the way for new
therapeutic approaches against schistosomiasis.
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